The geography of clinical trials has fundamentally changed. Sponsors are running trials across dozens of countries simultaneously, in pursuit of:
Faster enrollment.
Lower costs.
Patient populations that better reflect the world.
But here’s what hasn’t kept up: the way most organizations think about insurance.
Too often, insurance is treated as a last-minute compliance checkbox, something to handle once the science is settled and sites are selected. That approach is increasingly untenable. As clinical trials grow more complex, more distributed, and more costly to interrupt, the risk strategy has to be built in from the start.
Where you run your trial defines your risk
Emerging markets offer real advantages: lower per-patient costs, faster site activation, access to treatment-naïve populations. But every new geography brings a distinct regulatory and legal landscape. The jurisdiction where you run your trial determines:
The regulatory framework governing your study.
The legal standard of liability if a patient is harmed.
The specific insurance requirements you must satisfy.
These aren’t minor administrative details. They can determine whether a trial stalls, faces regulatory rejection, or exposes the sponsor to uninsured liability.
The myth of the standardized approach
One of the most persistent misconceptions in global trials is that regulatory and insurance requirements can be standardized across markets. They can’t. The variance across jurisdictions is significant and consequential:
Some countries require locally admitted clinical trial policies; global master programs won’t satisfy local regulators.
Others impose no-fault compensation frameworks that operate independently of negligence.
Many mandate specific coverage limits, policy language, or approved insurer structures.
Geopolitical instability, supply chain volatility, and the rise of advanced therapies and AI-driven development are introducing unprecedented risk exposures with little historical data to guide decision-making. As a result, the cost of misjudgment is higher than ever.
The real problem: visibility
Across jurisdictions, the challenge isn’t just complexity. It’s coordination. Many organizations lack real-time visibility into where their coverage stands, whether local requirements are being met, or how changes in one market ripple across a global program. Insurance documentation is scattered. Renewal timelines are missed. Compliance gaps go undetected until they become problems.
This is where the approach has to evolve: from reactive problem-solving to proactive, data-driven risk management.
Global reach. Local precision.
Global clinical trials will only grow more complex. The regulatory landscape is constantly shifting, new markets continue to open, and the therapies being studied are testing the boundaries of what insurance programs are designed to cover.
Success in this environment requires more than a good policy. It requires a strategy that balances global consistency with local precision, backed by experts who understand both the science and the risk.
Lockton’s dedicated Life Sciences team helps sponsors navigate this complexity with clarity, confidence, and control, ensuring insurance supports—not slows—the path to trial activation.
Coming Soon: Lockton Trial Connect
Lockton Trial Connect is a centralized clinical trial insurance platform designed to bring structure and control to global complexity. It gives sponsors and CROs a single place to manage their entire insurance program across every market, every protocol, every stage of development.
Through Trial Connect, users can:
Aggregate and manage coverage data across all trial locations in one view.
Filter by country, protocol, status, coverage type, and more.
Submit insurance requests, review quotes, and bind coverage, all within the platform.
Track compliance requirements and certificate issuance in real time.
The result is a coordinated, technology-enabled insurance strategy that moves at the speed of your clinical program, not weeks behind it.